LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. (LENZ): 7 pipeline candidates · ~9 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
8.7 months
D/E 0.11 · 0% dilution
Lead: Approved
7 candidates
N/A
3 buys · 0 sells (180d)
A transparent, data-derived signal for LENZ Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$208.6M
Cash
$24.8M
Quarterly Burn
$33.6M
Runway
8.7 mo
Revenue
$1.9M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| aceclidine | Phase 3 |
| aceclidine+brimonidine combination | Phase 3 |
| brimonidine | Phase 3 |
| lnz100 | Phase 3 |
| lnz101 | Phase 3 |
| vehicle | Phase 3 |
| vizz | Approved |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
141
Total value held
$222.7M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 4,178,823 | $38.2M |
| fmr llc | 3,597,784 | $32.9M |
| vanguard capital management llc | 2,082,376 | $19.1M |
| blackrock, inc. | 1,976,823 | $18.1M |
| franklin resources inc | 1,100,148 | $10.1M |
| millennium management llc | 869,257 | $8.0M |
| eversource wealth advisors, llc | 24,547 | $6.7M |
| morgan stanley | 648,848 | $5.9M |
| bank of america corp /de/ | 547,534 | $5.0M |
| geode capital management, llc | 524,574 | $4.8M |
Showing top 10 of 141 institutional holders of LENZ Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in LENZ Therapeutics, Inc.'s pipeline?
LENZ Therapeutics, Inc. (LENZ) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is LENZ Therapeutics, Inc.'s lead drug candidate?
LENZ Therapeutics, Inc.'s most advanced tracked candidate is aceclidine (Phase 3) for Presbyopia.
What is LENZ Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, LENZ Therapeutics, Inc. has approximately 8.7 months of cash runway.
What is LENZ Therapeutics, Inc.'s market capitalization?
LENZ Therapeutics, Inc.'s market capitalization is approximately $208.6M.
Who is the CEO of LENZ Therapeutics, Inc.?
Mr. Evert B. Schimmelpennink is the chief executive officer of LENZ Therapeutics, Inc. (LENZ).
Get the full picture on LENZ Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.